This site is intended only for healthcare professionals resident in Egypt 

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact Us

Menu

Close

Clinical Information Clinical Information Burden of meningococcal disease Serogroup distribution Nimenrix® immunogenicity Nimenrix® persistence Nimenrix® dose and administration Real-world impact Summary Important Safety Information Abbreviated Prescribing Information Support and Services Support and Services VideosWebinarsMaterialsSelf-detail Presentations

Nimenrix® dose & administration

Dosing schedule

Nimenrix® is approved as a single dose from 12 months of age.2

Nimenrix® is a licensed meningococcal conjugate vaccine for serogroups A, C, W-135, and Y that can be administered at age 6 weeks with no upper age limit and with broad age indication2
  

Adapted from Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine). [Local product document]. May 2022.

Safety profile

  
Preparation & Storage

Nimenrix® can be administered in a few steps.2
 


Route of administration2
Immunisation should carried out by intramuscular injection only. In infants, the recommended injection site is the anterolateral aspect of the thigh. In individuals aged ≥1 year, the recommended injection site is the anterolateral aspect of the thigh or the deltoid muscle.

Coadministration2
Nimenrix® allows concomitant administration with the standard vaccine calendar.2
​​​​​​ 
Find out moreLoading
Find out moreLoading

*In some situations, consideration may be given to administering an additional primary dose or a booster dose of Nimenrix®
†Nimenrix® should be used in accordance with official recommendations2
A second dose of Nimenrix® may be considered appropriate for some individuals.


DTaP, Diphtheria, tetanus, acellular pertussis; HiB, Haemophilus influenzae type B; IPV, Inactivated polio vaccine; HepB, Hepatitis B.

References:
  1. Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777-779.
  2. Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine). Egyptian Drug Authority leaflet approval date: 19/10/2022 Revision date: May 2022.
Click here for Nimenrix® Prescribing Information Loading

Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025

PP-NIM-EGY-0056

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


PP-UNP-EGY-0241
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 

If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
 

I confirm that I am a healthcare professional resident in Egypt.
 

PP-UNP-EGY-0241

Yes No
You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
 
PP-UNP-EGY-0241
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

PP-UNP-EGY-0241